Fig. 1
From: A multiplex immunoassay for the non-invasive detection of bladder cancer
Diagnostic performance of bladder cancer-associated molecular panel comprised of 10 biomarkers. a ROC curves were plotted to compare the performance characteristics of the MULTI-ARRAY® Assay (solid line) and the combined individual commercial ELISA assays (dotted line) in cohort #1 (62 subjects). Based on the area under the ROC curve (AUROC), Youden Index cutoff values that maximized the sum of sensitivity and specificity were determined for the combination of biomarkers. The MULTI-ARRAY® Assay achieved an overall sensitivity of 0.79 and specificity of 0.97 (AUROC 0.9258). The combination of data from the individual target ELISA assays achieved an overall sensitivity of 0.82 and specificity of 0.97 (AUROC 0.9467). b ROC curve to illustrate the performance characteristics of the MULTI-ARRAY® Assay in cohort #2 (200 subjects). The MULTI-ARRAY® assay achieved an overall sensitivity of 0.85 and specificity of 0.81 (AUROC 0.8880)